Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuanfei Baidu Granules for influenza-associated acute exacerbation of COPD
ChiCTR2500099984Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
- Start
- Apr 2025
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Xuanfei Baidu in chronic obstructive pulmonary disease (COPD) and influenza (2 arms), sponsored by Beijing Hospital of Traditional Chinese Medicine. Primary endpoints: Change from baseline in BCSS score at 7 days ±1 day after medication and Negative conversion rate of sputum culture at 7 days ±1 day in subjects with positive baseline sputum culture. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Xuanfei Baidu
03
Conditions
chronic obstructive pulmonary disease (COPD)influenza
Beyond the preview
Go deeper on ChiCTR2500099984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099984.